Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawle, H., Hess, D., Mueller, A., Thuerlimann, B.
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: April 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919988/
https://www.ncbi.nlm.nih.gov/pubmed/20740185
http://dx.doi.org/10.1159/000313838
_version_ 1782185227035082752
author Hawle, H.
Hess, D.
Mueller, A.
Thuerlimann, B.
author_facet Hawle, H.
Hess, D.
Mueller, A.
Thuerlimann, B.
author_sort Hawle, H.
collection PubMed
description We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission was temporarily lost after fulvestrant was tentatively withdrawn (63 months after treatment start), but was re-achieved after renewal of half-dose treatment and last reconfirmed 90 months after treatment start. The pharmacokinetic profile provides evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might explain both: toxicity and extraordinary efficacy.
format Text
id pubmed-2919988
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29199882010-08-25 Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer Hawle, H. Hess, D. Mueller, A. Thuerlimann, B. Case Rep Oncol Published: April 2010 We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission was temporarily lost after fulvestrant was tentatively withdrawn (63 months after treatment start), but was re-achieved after renewal of half-dose treatment and last reconfirmed 90 months after treatment start. The pharmacokinetic profile provides evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might explain both: toxicity and extraordinary efficacy. S. Karger AG 2010-04-29 /pmc/articles/PMC2919988/ /pubmed/20740185 http://dx.doi.org/10.1159/000313838 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: April 2010
Hawle, H.
Hess, D.
Mueller, A.
Thuerlimann, B.
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title_full Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title_fullStr Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title_full_unstemmed Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title_short Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
title_sort low-dose fulvestrant maintained long-term complete remission after poor response to previous endocrine therapies in a patient with advanced breast cancer
topic Published: April 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919988/
https://www.ncbi.nlm.nih.gov/pubmed/20740185
http://dx.doi.org/10.1159/000313838
work_keys_str_mv AT hawleh lowdosefulvestrantmaintainedlongtermcompleteremissionafterpoorresponsetopreviousendocrinetherapiesinapatientwithadvancedbreastcancer
AT hessd lowdosefulvestrantmaintainedlongtermcompleteremissionafterpoorresponsetopreviousendocrinetherapiesinapatientwithadvancedbreastcancer
AT muellera lowdosefulvestrantmaintainedlongtermcompleteremissionafterpoorresponsetopreviousendocrinetherapiesinapatientwithadvancedbreastcancer
AT thuerlimannb lowdosefulvestrantmaintainedlongtermcompleteremissionafterpoorresponsetopreviousendocrinetherapiesinapatientwithadvancedbreastcancer

Ejemplares similares